Evaluating the Therapeutic Profile of Immune Checkpoint Inhibitors in Advanced NSCLC: A Systematic Review
Prodip Chowdhury
Baccalaureate School for Global Education (BSGE), New York City, United States
Publication date: November 20, 2025
Baccalaureate School for Global Education (BSGE), New York City, United States
Publication date: November 20, 2025
DOI: http://doi.org/10.34614/JIYRC2025II46
ABSTRACT
In recent decades, immune checkpoint inhibitors (ICIs) have been acknowledged as a potential front-line treatment option for various cancers, including advanced non-small cell lung cancer (NSCLC). However, their usefulness in real-world clinical settings is unclear due to limited knowledge of their mechanisms and effects on the body. This systematic review intends to help bridge that gap by evaluating the efficacy and safety of ICIs in advanced NSCLC treatment. The databases Pubmed, Cochrane, and Google Scholar were searched, yielding 515 studies, of which 27 were included in the review. Studies demonstrated an association between ICIs, prolonged overall survival (OS) and progression-free survival (PFS), higher objective-response rates (ORR), and fewer treatment-related adverse events (TRAEs) compared to chemotherapy. However, their clinical benefits can be influenced by factors, including biomarker expression, toxicity, and patient health. Overall, ICIs demonstrate clinical benefits in patients with advanced NSCLC; however, additional research is necessary to optimize clinical use.
In recent decades, immune checkpoint inhibitors (ICIs) have been acknowledged as a potential front-line treatment option for various cancers, including advanced non-small cell lung cancer (NSCLC). However, their usefulness in real-world clinical settings is unclear due to limited knowledge of their mechanisms and effects on the body. This systematic review intends to help bridge that gap by evaluating the efficacy and safety of ICIs in advanced NSCLC treatment. The databases Pubmed, Cochrane, and Google Scholar were searched, yielding 515 studies, of which 27 were included in the review. Studies demonstrated an association between ICIs, prolonged overall survival (OS) and progression-free survival (PFS), higher objective-response rates (ORR), and fewer treatment-related adverse events (TRAEs) compared to chemotherapy. However, their clinical benefits can be influenced by factors, including biomarker expression, toxicity, and patient health. Overall, ICIs demonstrate clinical benefits in patients with advanced NSCLC; however, additional research is necessary to optimize clinical use.
